For the year ending 2025-12-31, SMMT has $751,182K in assets. $92,322K in debts. $225,266K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 225,266 | 104,862 | 71,425 | 348,607 |
| Restricted cash | 316 | 325 | 0 | 300,000 |
| Accounts receivable | - | - | 0 | 349 |
| Short-term investments | 488,182 | 307,487 | 114,817 | - |
| Prepaid expenses | - | - | 2,441 | 1,504 |
| Other current assets | - | - | 181 | 486 |
| Prepaid expenses and other current assets | 6,537 | 10,519 | - | - |
| Research and development tax credit receivable | - | 557 | 848 | 5,766 |
| Total current assets | 720,301 | 423,750 | 189,712 | 656,712 |
| Property and equipment, net | 1,059 | 254 | 204 | 906 |
| Operating lease right-of-use assets | 20,616 | 7,144 | 5,859 | 4,175 |
| Goodwill | 2,001 | 1,864 | 1,893 | 1,798 |
| Gross-Computer Software Intangible Asset-Utrophin Program | - | - | - | -4,015 |
| Accumulated amortization and impairment charges-Computer Software Intangible Asset-Utrophin Program | - | - | - | -4,015 |
| Gross-Computer Software Intangible Asset-Discuva Platform | - | - | - | -12,900 |
| Accumulated amortization and impairment charges-Computer Software Intangible Asset-Discuva Platform | - | - | - | -12,900 |
| Gross-Option Over Non Financial Assets | - | - | - | -816 |
| Accumulated amortization and impairment charges-Option Over Non Financial Assets | - | - | - | -816 |
| Gross-Other Patents And Licenses | - | - | - | -133 |
| Accumulated amortization and impairment charges-Other Patents And Licenses | - | - | - | -133 |
| Gross | - | - | - | -17,864 |
| Accumulated amortization and impairment charges | - | - | - | -17,864 |
| Intangible assets, net | - | - | - | 0 |
| Research and development tax credit receivable | - | 698 | 959 | - |
| Other assets | 7,205 | 1,850 | 4,322 | 577 |
| Total assets | 751,182 | 435,560 | 202,949 | 664,168 |
| Accounts payable | 20,292 | 4,636 | 2,667 | 355 |
| Accrued liabilities | 32,100 | 19,554 | 8,783 | 10,664 |
| Accrued compensation | 14,925 | 11,977 | 5,429 | 5,641 |
| Operating lease liabilities, current portion | 3,388 | 3,765 | 2,809 | 1,690 |
| Deferred revenue and other income | - | - | - | 0 |
| Other current liabilities | 2,283 | 1,797 | 717 | 662 |
| Promissory note payable to related parties | - | - | 0 | 19,770 |
| Total current liabilities | 72,988 | 41,729 | 20,405 | 38,782 |
| Operating lease liabilities, net of current portion | 17,502 | 3,453 | 3,290 | 2,763 |
| Other non-current liabilities | 1,832 | 1,630 | 1,562 | 1,429 |
| Promissory notes payable to related parties | - | - | - | 494,540 |
| Promissory note payable to a related party | - | 0 | 100,000 | - |
| Total liabilities | 92,322 | 46,812 | 125,257 | 537,514 |
| Common stock, 0.01 par value 1,000,000,000 shares authorized 775,371,200 and 737,626,004 shares issued and outstanding at december 31, 2025 and 2024, respectively | 7,754 | 7,376 | 7,017 | 2,110 |
| Additional paid-in capital | 2,947,805 | 1,598,230 | 1,066,381 | 504,767 |
| Accumulated other comprehensive loss | -2,540 | -2,285 | -2,448 | -1,893 |
| Accumulated deficit | -2,294,159 | -1,214,573 | -993,258 | -378,330 |
| Total stockholders' equity | 658,860 | 388,748 | 77,692 | 126,654 |
| Total liabilities and stockholders' equity | 751,182 | 435,560 | 202,949 | 664,168 |
Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (SMMT)